Avettand-Fènoël Véronique, Hocqueloux Laurent, Ghosn Jade, Cheret Antoine, Frange Pierre, Melard Adeline, Viard Jean-Paul, Rouzioux Christine
Université Paris-Descartes, Sorbonne Paris-Cité, Faculté de Médecine, EA 7327, Paris, France APHP, Hôpital Necker Enfants-Malades, Laboratoire de Virologie, Paris, France
CHR d'Orléans, Service de Maladies Infectieuses et Tropicales, Orléans, France.
Clin Microbiol Rev. 2016 Oct;29(4):859-80. doi: 10.1128/CMR.00015-16.
HIV-1 DNA persists in infected cells despite combined antiretroviral therapy (cART), forming viral reservoirs. Recent trials of strategies targeting latent HIV reservoirs have rekindled hopes of curing HIV infection, and reliable markers are thus needed to evaluate viral reservoirs. Total HIV DNA quantification is simple, standardized, sensitive, and reproducible. Total HIV DNA load influences the course of the infection and is therefore clinically relevant. In particular, it is predictive of progression to AIDS and death, independently of HIV RNA load and the CD4 cell count. Baseline total HIV DNA load is predictive of the response to cART. It declines during cART but remains quantifiable, at a level that reflects both the history of infection (HIV RNA zenith, CD4 cell count nadir) and treatment efficacy (residual viremia, cumulative viremia, immune restoration, immune cell activation). Total HIV DNA load in blood is also predictive of the presence and severity of some HIV-1-associated end-organ disorders. It can be useful to guide individual treatment, notably, therapeutic de-escalation. Although it does not distinguish between replication-competent and -defective latent viruses, the total HIV DNA load in blood, tissues, and cells provides insights into HIV pathogenesis, probably because all viral forms participate in host cell activation and HIV pathogenesis. Total HIV DNA is thus a biomarker of HIV reservoirs, which can be defined as all infected cells and tissues containing all forms of HIV persistence that participate in pathogenesis. This participation may occur through the production of new virions, creating new cycles of infection and disseminating infected cells; maintenance or amplification of reservoirs by homeostatic cell proliferation; and viral transcription and synthesis of viral proteins without new virion production. These proteins can induce immune activation, thus participating in the vicious circle of HIV pathogenesis.
尽管采用了联合抗逆转录病毒疗法(cART),HIV-1 DNA仍会在受感染细胞中持续存在,形成病毒储存库。最近针对潜伏性HIV储存库的策略试验重新燃起了治愈HIV感染的希望,因此需要可靠的标志物来评估病毒储存库。总HIV DNA定量简单、标准化、灵敏且可重复。总HIV DNA载量会影响感染进程,因此具有临床相关性。特别是,它可预测艾滋病进展和死亡,独立于HIV RNA载量和CD4细胞计数。基线总HIV DNA载量可预测对cART的反应。它在cART期间会下降,但仍可定量,其水平反映了感染史(HIV RNA峰值、CD4细胞计数最低点)和治疗效果(残余病毒血症、累积病毒血症、免疫恢复、免疫细胞激活)。血液中的总HIV DNA载量还可预测某些HIV-1相关终末器官疾病的存在和严重程度。它有助于指导个体化治疗,尤其是治疗降阶梯。尽管它无法区分具有复制能力和缺陷的潜伏病毒,但血液、组织和细胞中的总HIV DNA载量可深入了解HIV发病机制, 可能是因为所有病毒形式都参与宿主细胞激活和HIV发病机制。因此,总HIV DNA是HIV储存库的生物标志物,HIV储存库可定义为所有受感染的细胞和组织,这些细胞和组织包含参与发病机制的所有形式的HIV持续存在。这种参与可能通过产生新的病毒粒子、形成新的感染周期和传播受感染细胞来实现;通过稳态细胞增殖维持或扩大储存库;以及在不产生新病毒粒子的情况下进行病毒转录和病毒蛋白合成。这些蛋白质可诱导免疫激活,从而参与HIV发病机制的恶性循环。